Kyverna miv-cel holds disability gains in SPS at one-year mark
Kyverna Therapeutics has presented the full one-year dataset from KYSA-8, its registrational Phase 2 trial of miv-cel (mivocabtagene autoleucel) in stiff person syndrome, reporting that clinical benefits first observed at 16 weeks were sustained or deepened at the 12-month timepoint. The data were presented at MS Toronto 2026, the joint ACTRIMS-ECTRIMS meeting, on 21 October.
The trial enrolled 26 adult patients with SPS who had previously responded inadequately to at least one immunotherapy. All received a single infusion of miv-cel, an autologous CD19-targeting CAR T-cell therapy with CD28 co-stimulation. The primary endpoint, improvement in the timed 25-Foot Walk at 16 weeks, had been met with statistical significance at the earlier American Academy of Neurology readout; at one year, the median improvement from baseline in that measure reached 49%, fractionally above the 46% recorded at the primary endpoint.
Key efficacy and safety findings
At the one-year mark, 77% of patients achieved a clinically meaningful improvement in the T25FW test, defined as a 20% or greater reduction from baseline. More than a third completed the walk in under five seconds, a range described as typical for healthy adults. Of the 12 patients who had required a walking aid before treatment, 67% continued to manage without one. Secondary endpoints, including the Modified Rankin Scale, Hauser Ambulation Index, and measures of stiffness and hypersensitivity, all remained statistically significant. Exploratory endpoints pointed to continued deepening of response: median improvement in the six-minute walk test increased from 89 metres at week 16 to 119 metres at one year, roughly six times the accepted minimal clinically important change of 20 metres.
Ninety-two per cent of patients remained free of chronic immunotherapy for SPS at the one-year mark, a finding Kyverna regards as central to miv-cel's differentiated profile. The safety picture was consistent with earlier reports: no high-grade cytokine release syndrome, no immune effector cell-associated neurotoxicity syndrome, and no cases of IEC-HS. Grade 3/4 neutropenia occurred in five patients and was described as manageable; serious treatment-related adverse events arose in three patients and fully resolved.
Amanda Piquet, Director of Autoimmune Neurology at the University of Colorado Anschutz School of Medicine and lead investigator of KYSA-8, said: "The positive primary endpoint results, together with the secondary and exploratory endpoint data, highlight the full clinical benefit of miv-cel with a single dose."
Regulatory and competitive context
SPS affects an estimated 6,000 patients in the United States and currently has no FDA-approved treatment. Existing management relies on off-label immunotherapies such as intravenous immunoglobulin and rituximab, alongside symptomatic agents, and the majority of patients derive insufficient benefit. Kyverna is positioning the KYSA-8 dataset as the core of a biologics licence application package, with the company describing miv-cel as a potential first approved treatment for SPS and the first approved CAR T-cell therapy for any autoimmune disease.
The CAR T autoimmune space has attracted significant attention, with a small number of academic and industry groups pursuing CD19-directed approaches in conditions ranging from systemic lupus erythematosus to myasthenia gravis. Kyverna itself has an ongoing registrational trial in generalised myasthenia gravis and holds three FDA Regenerative Medicine Advanced Therapy designations, covering SPS, gMG, and non-active secondary progressive multiple sclerosis. The RMAT designation provides more intensive FDA interaction during development but does not guarantee approval.
The one-year durability data will be closely read by regulators and payers. Single-arm trial designs in rare disease are an accepted pathway, but absence of a control arm means that natural history variability and patient selection remain questions that the BLA will need to address. Kyverna has not announced a BLA filing date or a PDUFA date.